

Resource Summary Report

Generated by NIF on Jul 29, 2026

PerCP anti-human CD45

RRID:AB_893337

Type: Antibody

Proper Citation

BioLegend Cat# 304026, RRID:AB_893337

Antibody Information

URL: http://antibodyregistry.org/AB_893337

Proper Citation: BioLegend Cat# 304026, RRID:AB_893337

Target Antigen: CD45

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP anti-human CD45

Description: This monoclonal targets CD45

Target Organism: human

Clone ID: Clone HI30

Antibody ID: AB_893337

Vendor: BioLegend

Catalog Number: 304026

Alternative Catalog Numbers: 304025

Record Creation Time: 20250820T033550+0000

Record Last Update: 20250820T164031+0000

Ratings and Alerts

No rating or validation information has been found for PerCP anti-human CD45.

No alerts have been found for PerCP anti-human CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chen YL, et al. (2026) Endometrial stromal cell-derived TMAO sustains decidualization to prevent recurrent spontaneous abortion. *Cell metabolism*.

Li YR, et al. (2025) Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. *Nature protocols*, 20(5), 1352.

Fang Y, et al. (2025) Protocol to generate allojection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. *STAR protocols*, 6(2), 103810.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. *Med (New York, N.Y.)*, 100804.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Lam N, et al. (2025) Asynchronous aging and turnover of human circulating and tissue-resident memory T cells across sites. *Immunity*, 58(9), 2271.

Li YR, et al. (2025) Protocol to profile tumor and microenvironment from ovarian cancer patient samples and evaluate cell-based therapy using in vitro killing assays. *STAR protocols*, 6(2), 103742.

Vu LT, et al. (2024) Single-cell transcriptomics of the immune system in ME/CFS at baseline and following symptom provocation. *Cell reports. Medicine*, 5(1), 101373.

Li YR, et al. (2023) Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. *iScience*, 26(10), 107952.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. *Cell reports*, 42(12), 113516.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN- γ axis. *Cell reports*, 42(8),

112944.

Nuñez NG, et al. (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med (New York, N.Y.)*, 4(2), 113.

Vlassis A, et al. (2023) CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells. *iScience*, 26(12), 108287.

Laforêts F, et al. (2023) Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. *iScience*, 26(4), 106514.

Li YR, et al. (2022) Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers. *iScience*, 25(9), 104859.

Hu Y, et al. (2022) Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. *Cell research*, 32(11), 995.

Abdul-Jawad S, et al. (2021) Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. *Cancer cell*, 39(2), 257.

Parent AV, et al. (2021) Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. *Cell reports*, 36(7), 109538.

Li YR, et al. (2021) Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. *Cell reports. Medicine*, 2(11), 100449.

Szabo PA, et al. (2021) Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity*, 54(4), 797.